NASDAQ:RAIN
Delisted
Rain Therapeutics Inc. Stock News
$1.21
+0 (+0%)
At Close: Apr 24, 2024
3 Top Penny Stocks to Buy According To Insiders In October
10:35am, Monday, 16'th Oct 2023
Penny stocks, defined as stocks trading under $5 per share, offer traders huge upside potential but also carry significant risks. One strategy used by some investors to identify promising penny stocks
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
06:39pm, Thursday, 10'th Aug 2023
Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP,
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023
08:00am, Wednesday, 26'th Jul 2023
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and prov
Monish Pabrai on Finding Multi-Baggers and Intrinsic Valuation
04:55pm, Tuesday, 18'th Jul 2023
Mohnish Pabrai (Trades, Portfolio) is a legendary investor and the founder of Pabrai funds.
Why Shares of Rain Oncology Are Plummeting Today
03:15pm, Monday, 22'nd May 2023
Rain Oncology has milademetan in several trials. The oral therapy didn't show a big advantage over the current standard of care in treating dedifferentiated liposarcoma.
Why Is RAIN Stock Down 87% Today?
11:07am, Monday, 22'nd May 2023
Rain Oncology (NASDAQ: RAIN ) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company's Phase 3 M
Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Call Transcript
03:42am, Saturday, 13'th May 2023
Rain Oncology, Inc. (NASDAQ:RAIN ) Q1 2023 Earnings Conference Call May 11, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Br
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data
02:36am, Thursday, 27'th Apr 2023
Rain Oncology: Major Catalysts Ahead, With Supportive Prior Data.
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023
02:34pm, Wednesday, 26'th Apr 2023
Rain Oncology: Phase 3 Milademetan Data Expected Q2 Of 2023.
Rain Oncology Inc. (RAIN) Q4 2022 Earnings Call Transcript
09:04pm, Thursday, 09'th Mar 2023
Rain Oncology Inc. (NASDAQ:RAIN ) Q4 2022 Results Conference Call March 9, 2023 5:00 PM ET Company Participants Dan Ferry - LifeSci Advisors Avanish Vellanki - Chief Executive Officer Robert Doebele -
Rain Oncology to Present At Oppenheimer 33rd Annual Healthcare Conference
08:00am, Tuesday, 07'th Mar 2023
NEWARK, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, m
Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference
08:00am, Monday, 14'th Nov 2022
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a late-stage biotechnology company developing precision oncology therapeutics with a lead produc
Rain Therapeutics Inc. (RAIN) Q3 2022 Earnings Call Transcript
10:43pm, Saturday, 12'th Nov 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Dan Ferry – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Rob
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
08:00am, Thursday, 27'th Oct 2022
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead produ
Rain Therapeutics Inc.'s (RAIN) CEO Avanish Vellanki on Q2 2022 Results - Earnings Call Transcript
10:49am, Saturday, 06'th Aug 2022
Rain Therapeutics Inc. (NASDAQ:RAIN ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Bob Yedid – LifeSci Advisors Avanish Vellanki – Chief Executive Officer Nelson
